论文部分内容阅读
目的:探讨复方甘草酸苷在原发性肝癌肝动脉碘油栓塞术(TACE)后的保肝降酶作用。方法:原发性肝癌65例,随机分为治疗组35例和对照组30例,治疗组每次TACE术后即予以复方甘草酸苷60ml静脉滴注,2周后给予复方甘草酸苷片,1次50mg,每天3次,口服;对照组给予强力宁60ml静脉滴注,2周后予护肝片,1次2片,每天3次,口服。结果:首次TACE治疗后治疗组出现ALT和/或AST升高9例,对照组16例,但ALT、AST测定值两组差异无显著性意义,P>0.05;2次TACE术后,治疗组ALT和AST值显著低于对照组,P<0.05。结论:复方甘草酸苷对原发性肝癌TACE术后具有较好的保肝降酶作用。
OBJECTIVE: To investigate the protective effect of compound glycyrrhizin on hepatoprotection and down-regulation of hepatic artery after hepatic artery lipiodol embolization (TACE). Methods: Sixty-five cases of primary liver cancer were randomly divided into treatment group (35 cases) and control group (30 cases). The treatment group received compound glycyrrhizin 60 ml intravenously after each TACE, and compound glycyrrhizin tablets were given after 2 weeks. Once 50mg, 3 times a day, oral; control group given strong Lining 60ml intravenous infusion, 2 weeks after the Hugan tablets, 2 tablets, 3 times a day, orally. Results: After the first TACE treatment, there were 9 cases of ALT and/or AST elevation in the treatment group and 16 cases in the control group. There was no significant difference in the ALT and AST values between the two groups, P>0.05; after 2 TACE treatment, the treatment group The ALT and AST values were significantly lower than the control group, P<0.05. Conclusion: Compound glycyrrhizin has better hepatoprotective and enzymatic effects on primary liver cancer after TACE.